PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD

December 04, 2018
BH19-027
Genetics, Cancer, Surgery
Mary-Alice Abbott, MD
Baystate Medical Center, 759 Chestnut St, Springfield, MA; Baystate Children’s Specialty Center, 50 Wason Avenue, Springfield, MA
The purpose of this research study is to compare the effectiveness of a new investigational combination treatment, called ATB200 and AT2221, with the current standard medication, called Lumizyme®/Myozyme®, or alglucosidase alfa. The purpose is to see how the treatments compare in treating patients with Pompe disease.
• Male and female subjects are ≥ 18 years old and weigh ≥ 40 kg
• Subject must have a diagnosis of LOPD
Approximately 14 months
Recruiting
Interventional (Clinical Trial)
3
Victoria Cobb
413-794-1466